Whether a Program Allows Medication Is a Quality Signal

Why medication is a yes-or-no vetting question

Whether a program offers or forbids medication is a fast, revealing screen because current clinical guidelines take a clear position. The ASAM National Practice Guideline recommends treating opioid use disorder with methadone or buprenorphine rather than withdrawal management alone, says no medication should be withheld because someone is still using other substances, and says medication should not be arbitrarily time-limited 1Ref 1American Society of Addiction Medicine (2020).The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder — 2020 Focused Update.The guideline of record recommends treating opioid use disorder with methadone or buprenorphine rather than withdrawal management alone, holds that no medication should be withheld because of ongoing use of other substances, and that medication should not be arbitrarily time-limited.. A program that refuses medication on principle, or makes coming off it a condition of admission, is out of step with the guideline of record. You do not have to resolve the underlying medication versus abstinence-only question yourself to notice when a program's policy contradicts the evidence.

What the medications are, briefly

Medication for addiction treatment is a defined set of FDA-approved options, not a vague category. For opioid use disorder, the three FDA-approved medications are methadone, buprenorphine, and naltrexone 2Ref 2Substance Abuse and Mental Health Services Administration (2021).TIP 63: Medications for Opioid Use Disorder — Full Document.The three FDA-approved medications for opioid use disorder are methadone, buprenorphine, and naltrexone.. For alcohol use disorder, three medications are FDA-approved, naltrexone, acamprosate, and disulfiram, and they are non-addictive, can be used with or without counseling, and are substantially underused 3Ref 3National Institute on Alcohol Abuse and Alcoholism (2024).Recommend Evidence-Based Treatment: Know the Options.Three FDA-approved medications treat alcohol use disorder — naltrexone, acamprosate, and disulfiram — which are non-addictive, can be used with or without counseling, and are substantially underused.. This article treats these as a vetting signal only; the detail of how each one works belongs elsewhere. What you need for vetting is simpler: a program serving opioid or alcohol use disorder should be able to offer, or promptly connect you to, this medication-assisted treatment when it is clinically indicated, and understanding what medication-assisted treatment is at a high level is enough to ask the question well.

Why forbidding medication is a meaningful red flag

A blanket no-medication policy is a red flag because for opioid use disorder the evidence connecting medication to survival is unusually strong. A study of six treatment pathways in 40,885 adults with opioid use disorder found that only buprenorphine or methadone was associated with reduced overdose and serious opioid-related acute care use at 3 and 12 months, while inpatient and residential treatment and intensive behavioral interventions were not 4Ref 4Wakeman SE, Larochelle MR, Ameli O, et al. (2020).Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.Among six treatment pathways in 40,885 adults with opioid use disorder, only buprenorphine or methadone was associated with reduced overdose and serious opioid-related acute care use at 3 and 12 months, while inpatient/residential and intensive behavioral interventions were not.. In a landmark meta-analysis, all-cause mortality was roughly 11.3 versus 36.1 per 1,000 person-years for people in versus out of methadone treatment 5Ref 5Sordo L, Barrio G, Bravo MJ, et al. (2017).Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.Retention on methadone or buprenorphine is associated with substantially lower all-cause and overdose mortality than being out of treatment, with all-cause mortality roughly 11.3 versus 36.1 per 1,000 person-years in versus out of methadone treatment.. A program entitled to its philosophy is still choosing, when it forbids medication, an approach the mortality data does not support. That is worth weighing heavily as you are vetting a rehab. The stakes here are not abstract. For someone leaving a period of opioid use, the weeks after a residential stay are a high-risk window, and being connected to medication rather than steered away from it is one of the few interventions with survival evidence behind it. A no-medication policy is not a neutral stylistic difference between programs; it is a decision that changes the odds.

Not every good program dispenses medication on-site

A program can be medication-supportive without running its own pharmacy, so the honest test is the attitude and the connection, not the on-site dispensary. Methadone specifically is dispensed only through federally regulated opioid treatment programs under 42 CFR Part 8, and a 2024 final rule expanded access, adding take-home doses, telehealth initiation, and removing the prior requirement of a year of addiction before admission 6Ref 6Substance Abuse and Mental Health Services Administration (2024).42 CFR Part 8 Final Rule.Opioid treatment programs dispensing methadone are federally regulated under 42 CFR Part 8, and the 2024 final rule expanded access through take-home doses, telehealth initiation, and removal of the prior one-year-of-addiction admission requirement.. So a residential program will often coordinate methadone through a licensed opioid treatment program rather than dispense it itself.

The distinction that matters is between coordinating and refusing. A good program will help you get on or stay on medication and will connect you to a prescriber; finding a suboxone prescriber through SAMHSA's practitioner locator is something a supportive program will assist with, not obstruct. A program that actively bars medication, or requires you to stop it to enroll, is the one whose policy should give you pause.

The questions that surface the policy

Ask the policy directly, because a program's real stance surfaces fast under a few specific questions. Put to the admissions line: will you start or continue medication if it is indicated; will you keep me on medication I already take; do you require anyone to taper off medication to be admitted; and how do you connect people to methadone or buprenorphine if you do not provide it here. These belong on any list of questions to ask a rehab before you commit.

• "Will you continue my current medication?" A no, or a required taper, is a red flag.
• "Is medication available if it is indicated for me?" A supportive program says yes and explains how.
• "How do you coordinate methadone or buprenorphine you don't dispense?" A real answer names a locator or a partner clinic.

Stance matters for behavioral treatments too. For stimulant use disorder, where no medication is FDA-approved, contingency management is a strongly evidence-based option, and a quality program can name it 7Ref 7National Academies of Sciences, Engineering, and Medicine (2023).Contingency Management for the Treatment of Substance Use Disorders: Enhancing Access, Quality, and Program Integrity for an Evidence-Based Intervention.Contingency management is a strongly evidence-based behavioral treatment and among the most effective for stimulant use disorder, for which no medication is FDA-approved.. Whether a program leans independent or chain, the medication question cuts across the whole field, and knowing the differences between independent vs chain rehab is a separate layer of the same vetting.

Where to check and where to start

Use neutral government tools to find programs and confirm what they offer, rather than a commercial helpline that may steer you. SAMHSA maintains official treatment locators, including buprenorphine-practitioner and opioid-treatment-program finders, so you can identify medication-providing programs directly 8Ref 8Substance Abuse and Mental Health Services Administration (2024).Treatment Locators: Mental Health, Drug, Alcohol Issues.SAMHSA maintains official treatment locators, including buprenorphine-practitioner and opioid-treatment-program finders, so a person can identify medication-providing programs through a neutral government source.. FindTreatment.gov is the federal government's free, confidential, and anonymous locator of state-licensed treatment facilities for mental and substance use disorders 9Ref 9Substance Abuse and Mental Health Services Administration (2024).FindTreatment.gov.FindTreatment.gov is the federal government's free, confidential, anonymous locator of state-licensed treatment facilities for mental and substance use disorders..

Using those tools, you can filter toward programs that offer medication and then ask each one the policy questions above. The medication stance is not the only thing that matters, but it is one of the few quality signals you can read quickly, check against a published guideline, and use to rule a program in or out. For people whose lives intersect with the justice system, the same question carries added weight, and the specifics of MAT in jail and prison are their own subject.